Notice of special administration instructions for Zemaira. Read more here
For Patients

References

  1. Petrache I, Hajjar J, Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics. 2009;3:193-204.
  2. Alpha-1 Foundation website. What is Alpha-1? http://alpha-1foundation.org/what-is-alpha-1. Accessed January 29, 2018.
  3. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360(26):2749-2757.
  4. Rachelefsky G, Hogarth DK. Issues in the diagnosis of alpha 1-antitrypsin deficiency. J Allergy Clin Immunol. 2008;121(4):833-838.
  5. National Heart, Lung, and Blood Institute website. What is Alpha-1 Antitrypsin Deficiency? https://www.nhlbi.nih.gov/health/health-topics/topics/aat. Accessed January 29, 2018.
  6. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.
  7. Siri D, Farah H, Hogarth DK. Distinguishing alpha1-antitrypsin deficiency from asthma. Ann Allergy Asthma Immunol. 2013;111(6):458-464.
  8. Dewar M, Curray RW Jr. Chronic obstructive pulmonary disease: diagnostic considerations. Am Fam Physician. 2006;73(4):669-676.
  9. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with α1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186.
  10. Data on file. Available from CSL Behring as DOF ZMR-001.
  11. Alpha-1 Foundation website. Family testing. http://alpha-1foundation.org/its-all-in-the-family. Accessed January 29, 2018.
  12. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;6(3):668-682.
  13. Stocks JM, Brantly M, Pollock D, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new α1-proteinase inhibitor, Zemaira. COPD. 2006;3(1):17-23.
  14. Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008;3:16.
  15. Data on file. Available from CSL Behring as DOF ZMR-002.
You are now leaving the current website.